Life-changing gene therapies for hemophilia have become available, yet many patients and providers have not yet rushed to try ...

Otis has received several blood transfusions over the years at UC Davis, which is sourced by UC Davis from local volunteers.

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

UC San Diego Health one of a few health care systems on West Coast to offer new gene therapy for hemophilia B.

Bleeding Disorders market Growth. PORTLAND, OR, UNITED STATES, January 6, 2025 /EINPresswire / -- The global bleeding disorders market is undergoing signif ...

Novartis’ NVS phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

These cells are, according to Karin, “like ticking time bombs that could start proliferating again at any point and ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.